Pflug Koory LLC Buys 181 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Pflug Koory LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,866 shares of the medical equipment provider’s stock after purchasing an additional 181 shares during the quarter. Pflug Koory LLC’s holdings in Zimmer Biomet were worth $353,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Stock Yards Bank & Trust Co. increased its position in shares of Zimmer Biomet by 7.9% during the 2nd quarter. Stock Yards Bank & Trust Co. now owns 2,841 shares of the medical equipment provider’s stock valued at $259,000 after purchasing an additional 208 shares during the last quarter. Hilltop National Bank bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. grew its position in Zimmer Biomet by 7.9% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,912 shares of the medical equipment provider’s stock valued at $2,455,000 after acquiring an additional 1,971 shares during the last quarter. New Wave Wealth Advisors LLC grew its position in Zimmer Biomet by 16.8% in the 2nd quarter. New Wave Wealth Advisors LLC now owns 2,431 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 349 shares during the last quarter. Finally, Truist Financial Corp grew its position in Zimmer Biomet by 34.4% in the 2nd quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after acquiring an additional 6,867 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Royal Bank Of Canada upped their price objective on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. UBS Group upped their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Saturday, September 27th. Raymond James Financial upped their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Stifel Nicolaus upped their price objective on Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research report on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $112.44.

Zimmer Biomet Price Performance

ZBH opened at $100.81 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The business’s fifty day simple moving average is $100.87 and its 200-day simple moving average is $98.81. The company has a market capitalization of $19.97 billion, a price-to-earnings ratio of 24.53, a PEG ratio of 2.28 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the company earned $2.01 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.